CLARA CABRERA FERMIN: Open Payments
NPI 1669902011 · DILLON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$499 in 28 payments from 14 companies in 2025. Trend: 2023 $341 · 2024 $602 · 2025 $499
Food & beverage: $499
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $165 |
| Novo Nordisk Inc | 2 | $52 |
| Dexcom, Inc. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Exact Sciences Corporation | 2 | $33 |
| GlaxoSmithKline, LLC. | 2 | $32 |
| Lilly USA, LLC | 2 | $29 |
| Abbott Laboratories | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| PFIZER INC. | 1 | $16 |
Products named: VRAYLAR, Ozempic, Dexcom G6 Transmitter, CAPLYTA, Cologuard Collection Kit, TRELEGY ELLIPTA, REXULTI, MOUNJARO.
Industry payments across SC — which companies pay providers there.
